Inventor · disambiguated record
Jian-Feng Lu
Also filed as: LU JIAN · LU JIAN FENG · LU JIAN J · LU JIAN-FENG (JEFF)
15 granted patents·22 pending applications·198 citations·filing 2004–2024
92Inventor score
Top patents by PatentIndex Score
37 records- 0195US11746147B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2020·Granted Sep 5, 2023·4 cites·5 claims
- 0295US7449184B2Fixed dosing of HER antibodiesGENENTECH INC·Filed 2005·Granted Nov 11, 2008·138 cites·32 claims
- 0393US11059885B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2019·Granted Jul 13, 2021·7 cites·7 claims
- 0493US10654922B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2017·Granted May 19, 2020·8 cites·7 claims
- 0591US10487112B2Pediococcus acidilactici derived antimicrobial hexapeptide and preparation method thereofUNIV JIANGNAN·Filed 2016·Granted Nov 26, 2019·2 cites·4 claims
- 0689US8404234B2Fixed dosing of HER antibodiesALLISON DAVID E·Filed 2008·Granted Mar 26, 2013·25 cites·9 claims
- 0788US12043662B2Angiopoietin 2, VEGF dual antagonistsASKGENE PHARMA INC·Filed 2021·Granted Jul 23, 2024·1 cites·2 claims
- 0887US10077308B2PD-L1 specific monoclonal antibodies for disease treatment and diagnosisASKGENE PHARMA INC·Filed 2017·Granted Sep 18, 2018·6 cites·14 claims
- 0986US11845801B2IL-15 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2020·Granted Dec 19, 2023·2 cites·21 claims
- 1085US11505618B2Antibodies and methods for making and using the sameASKGENE PHARMA INC·Filed 2019·Granted Nov 22, 2022·2 cites·16 claims
- 1183US10287336B2Feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2015·Granted May 14, 2019·3 cites·7 claims
- 1280US2025188160A1Novel angiopoietin 2, vegf dual antagonistsASKGENE PHARMA INC·Filed 2024·Application pending·0 cites
- 1379US2023212311A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2022·Application pending·0 cites
- 1478US2024101655A1Novel Angiopoietin 2, VEGF Dual AntagonistsASKGENE PHARMA INC·Filed 2023·Application pending·0 cites
- 1575US12312413B2Antibodies and methods for making and using the sameASKGENE PHARMA INC·Filed 2022·Granted May 27, 2025·0 cites·14 claims
- 1672US2025127858A1Novel cytokine prodrugsASKGENE PHARMA INC·Filed 2024·Application pending·0 cites
- 1771US2020239595A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2019·Application pending·0 cites
- 1869US2024067739A1Novel il-15 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2023·Application pending·0 cites
- 1963US10626380B2Laccase producing compositionUNIV JIANGNAN·Filed 2019·Granted Apr 21, 2020·0 cites·8 claims
- 2063US2015093381A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2014·Application pending·0 cites
- 2163US2018327510A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2018·Application pending·0 cites
- 2262US2025215364A1Malt production method and method for improving antioxidant activity of maltLAIR LIQUIDE SA POUR IETUDE ET LEXPLOITATION DES PROCEDES GEORGES CLAUDE·Filed 2024·Application pending·0 cites
- 2360US2019248858A1Novel feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 2459US2013142865A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2013·Application pending·0 cites
- 2559US2017037147A1Fixed dosing of her antibodiesGENENTECH INC·Filed 2016·Application pending·0 cites
- 2657US2021260163A1Novel cytokine prodrugsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 2754US10266812B2Laccase producing compositionUNIV JIANGNAN·Filed 2016·Granted Apr 23, 2019·0 cites·5 claims
- 2851US2023135521A1Pharmaceutical formulations for novel feline erythropoietin receptor agonistsASKGENE PHARMA INC·Filed 2019·Application pending·0 cites
- 2949US2022289822A1Novel il-21 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 3048US2023086152A1Use of desloratadine and salts thereof in preparing drug for treating neurodegenerative disease related to motor dysfunctionUNIV NANJING CHINESE MEDICINE·Filed 2021·Application pending·0 cites
- 3148US2004147447A1TNFR-like protein with death domainASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 3246US2019106494A1PD-L1 Specific Monoclonal Antibodies for Disease Treatment and DiagnosisASKGENE PHARMA INC·Filed 2018·Application pending·0 cites
- 3342US2012220035A1Temperature-responsive co-polymers and uses thereofLU JIAN·Filed 2010·Application pending·0 cites
- 3442US2018055944A1Novel antibody-albumin-drug conjugates (aadc) and methods for using themASKGENE PHARMA INC·Filed 2017·Application pending·0 cites
- 3541US11060012B2Deposit disintegrator compositionsSHELL OIL CO·Filed 2017·Granted Jul 13, 2021·0 cites·20 claims
- 3638US2016137712A1Fusion Proteins With Dual Receptor Agonist ActivitiesASKGENE PHARMA INC·Filed 2015·Application pending·0 cites
- 3738US2014037642A1Methods and compositions relating to inhibition of igf-1rMCCAFFERY IAN·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jian-Feng Lu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →